EC Microbiology

Editorial Volume 21 Issue 6 - 2025

Engross and Submerge-Rosai Dorfman Disease

Anubha Bajaj*

Department of Histopathology, Panjab University, A.B. Diagnostics, India

*Corresponding Author: Anubha Bajaj, Department of Histopathology, Panjab University, A.B. Diagnostics, India.
Received: May 27, 2025; Published: June 03, 2025




Rosai Dorfman disease occurs as an exceptionally encountered, non-Langerhans cell histiocytosis accompanied by heterogeneous clinical features. An estimated 40% individuals depict extra-nodal disease which may be confined to specific sites or emerge as disseminated disease. The disorder may be familial or concur with neoplasia or immune disease.

  1. Rosai J and Dorfman RF. “Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity”. Archives of Pathology 1 (1969): 63-70.
  2. Tran PTC., et al. “Clinicopathological characteristics of extranodal Rosai-Dorfman disease: A retrospective case series of 25 patients”. Annals of Diagnostic Pathology 73 (2024): 152377.
  3. Werneck Rodrigues DO., et al. “Case study: Rosai-Dorfman disease and its multifaceted aspects”. Journal of Blood Medicine 15 (2024): 123-128.
  4. Cronin C., et al. “Case report: BRAF-inhibitor therapy in BRAF-mutated primary CNS tumours including one case of BRAF-mutated Rosai-Dorfman disease”. Frontiers in Medicine (Lausanne) 9 (2022): 1070828.
  5. Jafri ZA., et al. “KRAS 117N positive Rosai-Dorfman disease with atypical features”. Journal of Cutaneous Pathology 1 (2021): 147-150.
  6. Garces S., et al. “Cyclin D1 expression in Rosai-Dorfman disease: A near-constant finding that is not invariably associated with mitogen-activated protein kinase/extracellular signal-regulated kinase pathway activation”. Human Pathology 121 (2022): 36-45.
  7. Azari-Yaam A., et al. “Rosai-Dorfman disease: a rare clinicopathological presentation and review of the literature”. Head and Neck Pathology 1 (2021): 352-360.
  8. Dufour J., et al. “BRAF mutation in overlapping form of Erdheim-Chester and Rosai Dorfman diseases: A unique case restricted to the central nervous system”. Revue Neurologique (Paris)6 (2021): 708-710.
  9. Durham BH., et al. “Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms”. Nature Medicine 12 (2019): 1839-1842.
  10. Baraban E., et al. “Cyclin D1 expression and novel mutational findings in Rosai-Dorfman disease”. British Journal of Haematology 6 (2019): 837-844.
  11. Image 1 Courtesy: Libre Pathology.
  12. Image 2 Courtesy: MDPI.

Anubha Bajaj. “Engross and Submerge-Rosai Dorfman Disease”. EC Microbiology  21.6 (2025): 01-05.

ECronicon Journal

Our Services

Quick Links

Information

Creative Commons LicenseOpen Access by ECronicon is licensed under a Creative Commons Attribution 4.0 International License
Based on a work at www.ecronicon.net